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1. Introduction
Cardiovascular diseases (CVDs) are the leading causes of death
worldwide, leading to 18 million deaths annually.[1] CVD is
estimated to remain the main cause of mortality, resulting in
24 million global deaths per year by 2030.[2] The dominant cause
of CVD is atherosclerosis, which is an inflammation-driven dis-
ease of the arteries.[3] This number-one killer disease results in
the formation of atherosclerotic plaques on
arterial walls and can eventually cause
thrombosis, myocardial infarction, and
ischemic stroke.[4,5] Despite the growing
need for new and improved atherosclerosis
therapies, the FDA approvals for new ath-
erosclerotic therapeutics decreased during
the past decade.[2] One of the reasons behind
this problem is the lack of predictive and
effective disease models to test novel thera-
peutics prior to clinical studies.[6,7] In vivo
models are lengthy, costly, labor intensive,
ethically problematic, and poor predictors
of human responses.[7] In contrast, conven-
tional in vitro models cannot fully replicate
the pathophysiological condition of this dis-
ease.[8] A suitable vascular disease model
should be able to mimic the physiological
condition of a vessel (e.g., vessel dimen-
sions, flow rate, shear stress, etc.) and
the relevant pathological condition of the
disease. To overcome the shortcomings of
the conventional in vitro and in vivo models,
biomicrofluidic vascular models have
recently gained significant attention.[8–11]
To develop a biomimetic and biomicrofluidic model for ath-
erosclerotic research, we focused on dysfunctional endothelium
(Dys-En) as one of the main characteristics of atherosclerosis. In
a healthy vessel, nutrients and oxygen are supplied to the intima
by their diffusion from the lumen. Furthermore, a microvascu-
lature network called “vasa vasorum,” supplies oxygen and
nutrients to the outer compartment of the vessel walls[12,13]
(Figure 1a). Due to the plaque formation in an atherosclerotic
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The internal surfaces of all blood and lymphatic vessels are lined with an
endothelium, which tightly controls and regulates the permeability of biological
molecules. A dysfunctional endothelium (Dys-En) is a hallmark of many diseases,
including atherosclerosis. Dys-En in atherosclerosis leads to loss of adherens
junctions between cells, thus enhancing permeability and upregulation of
adhesion receptors such as vascular cell adhesion molecule 1 (VCAM-1). Both
this enhanced permeability of the endothelium and associated upregulated
endothelial cell surface receptors can be exploited in nanomedicine targeting to
atherosclerotic plaques. However, the relationship between targeting ligand and
nanoparticle (NP) size is not well understood within this context. Herein, a
biomicrofluidic model of Dys-En is developed and this platform is used to screen
VCAM-1 targeted NPs. Screening of NPs with varying properties under flow
shows that size plays a dominant role in NP targeting, with NPs in the range of
30–60 nm showing increased targeting to Dys-En. Moreover, treatment of Dys-
En-on-a-chip with Annexin A1, as a novel proresolving mediator of inflammation,
results in restoration of adherens junctions and normalization of the barrier
integrity. The results demonstrate utility of using “Dys-En-on-a-chip” as a
screening platform for Dys-En-targeted nanomedicines and biologics.
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vessel, the intima thickens, resulting in an insufficient and
impaired diffusion of oxygen and nutrients from the lumen to
the intima. To restore oxygen and nutrient supply, neovasculari-
zation occurs and the “vasa vasorum” sprouts into the atheroscle-
rotic plaque.[14,15] In contrast to a healthy endothelium (En), the
endothelium on these intraplaque neovessels is inflamed and a
Dys-En ensues[16] (Figure 1b).
The importance of Dys-En in atherosclerotic therapy can be
divided into two main categories: 1) targeting of drug delivery
systems to atherosclerotic plaques based on unique targeting
opportunities provided by Dys-En such as leaky vessels and upre-
gulated receptors (Figure 1c) and 2) restoration and normaliza-
tion of Dys-En to prevent chronic inflammation (Figure 1d).
Targeted nanoparticles (NPs) are being intensively investigated
for diagnosis and treatment of atherosclerosis,[16–19] and Dys-
En provides unique opportunities to target NPs to atherosclerotic
plaques.[16] Dys-En cannot regulate the barrier integrity, which
leads to disrupted cellcell junctions, thus enhancing permeabil-
ity.[20,21] Therefore, NPs can extravasate from blood circulation
into the plaque.[9,16] Moreover, overexpression of adhesion mol-
ecules such as vascular cell adhesionmolecule 1 (VCAM-1) is one
of the key biological manifestation of a Dys-En.[22,23] Therefore,
both enhanced permeability and overexpression of VCAM-1
are promising strategies to target NPs to atherosclerotic
plaques[24–27] (Figure 1c). In fact, several studies up to now have
utilized VCAM-1 as a marker for targeted drug delivery using
NPs targeted to a wide range of abnormal endothelia.[28,29] A
recent study also showed that targeting of NPs to VCAM-1
is most efficient in the inflamed cerebral vasculature.[30]
Furthermore, Dys-En permits lipoproteins and leukocytes to
enter the intima, which initiates chronic inflammation and con-
tributes to plaque growth, especially in early atherosclerosis.[5,31]
Therefore, normalization and restoration of a compromised and
leaky endothelium by novel anti-inflammatory and resolving
mediators (e.g., Annexin A1) can be a potent therapeutic strategy
for atherosclerosis[32,33] (Figure 1d).
In this study, we first fabricated a three-layered microchip,
consisting of two polydimethylsiloxane (PDMS) layers separated
by a semipermeable membrane layer. Next, endothelial cells
were cultured on the membrane using microfluidic cell culture
techniques to develop a biomimetic model of endothelium-on-a-
chip (En-on-a-chip). The established En-on-a-chip was inflamed
using a proinflammatory cytokine to develop a dysfunctional-
endothelium-on-a-chip (Dys-En-on-a-chip), which could success-
fully mimic the enhanced permeability, overexpression of
VCAM-1, and the shear condition of a Dys-En. Then, we used
the developed biomicrofluidic models to 1) screen and under-
stand VCAM-1-targeted NP permeability and binding to Dys-
En as a function of NP biophysicochemical properties for more
effective drug delivery to the plaque and 2) investigate the restor-
ative effect of Annexin A1 on Dys-En. A few studies have
investigated binding of VCAM-1-targeted NPs to Dys-En under
microfluidic shear conditions.[34–37] However, a comprehensive
study to investigate the effect of NP properties (i.e., size, VCAM-1
peptide density, zeta potential, and polydispersity index [PDI]) on
NP permeability and binding across healthy and Dys-En-on-a-
chip under flow conditions is yet to be reported. VCAM-1 is
not only overexpressed in atherosclerosis, and vascular inflam-
mation manifests in a wide range of other disease conditions,[4]
where our screening chip can therefore have a much broader util-
ity, and it is why we chose to investigate VCAM-1 targeting in this
instance. In addition, we chose to investigate the proresolving
effects of Annexin-A1 on Dys-En because this protein has
recently attracted significant attention in the field of anti-
inflammatory drug discovery.[33,38,39] Annexin A1 can mimic
how inflammation naturally subsides in the body; thus, it has
fewer side effects than current anti-inflammatory drugs.[33] It
has also been reported that Annexin A1 can show positive effects
to restore the damaged bloodbrain barrier (BBB).[40–42]
However, the restorative and proresolving effects of Annexin
A1 on Dys-En as therapeutic strategies for CVD are yet to be
investigated.
2. Results and Discussions
2.1. Development of En-on-a-Chip and Dys-En-on-a-Chip
In the first instance, we developed a microfluidic platform incor-
porating a monolayer of endothelial cells exposed to flow and
shear stress, to be able to mimic the physiological environment
of a vessel. For this purpose, we used a microfluidic chip consist-
ing of three layers. The upper and lower layers were made
of PDMS and fabricated by standard photolithography
(Figure S1, Supporting Information) and soft lithography
Figure 1. a) Structure of a vasa vasorum on a healthy vessel wall.
b) Structure of a neovessel sprout from a vasa vasorum into an athero-
sclerotic plaque. The endothelium on these intraplaque neovessels is
inflamed and Dys-En. We developed a Dys-En-a-chip in this study and used
it to investigate: c) NP targeting to atherosclerotic lesions based on unique
targeting opportunities provided by Dys-En (i.e., enhanced permeability
and VCAM-1 overexpression) and D) restoration and normalization of
Dys-En by an anti-inflammatory and resolving mediator (i.e., Annexin A1).
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procedures. Each PDMS layer contained a channel with the
dimensions of 6 0.4mm as the main channel, which was con-
nected to two side channels with the dimensions of 3 0.4mm.
Two circles (2 mm diameter) were considered as the access
points to the channels to prevent leakage at the inlet and outlet
points. A thin layer of semipermeable polyethylene terephthalate
(PET) membrane was bonded between these PDMS layers. This
membrane not only separated the upper and lower channels, but
also provided suitable support for culturing of endothelial cells.
The schematic and photographic representation of the fabricated
chip can be seen in Figure 2a,b–d, respectively. After fabrication
of the chip, the porous membrane was treated with fibronectin to
promote the cell attachment. Human umbilical vein endothelial
cells (HUVECs) were then cultured on the membrane by micro-
fluidic cell culture techniques. The schematic representation of
the developed biomicrofluidic system and the full coverage of the
membrane by the cells can be seen in Figure 2e,f, respectively.
Various drugs (e.g., Annexin A1) and NPs (e.g., VCAM-1-
targeted NPs) can be perfused through the upper channel and
their interaction with the endothelium under physiological shear
conditions can be studied not only by collecting the samples from
the lower channel, but also using microscopy techniques. The
components of the microfluidic cell culture setup developed
in this study are shown in Figure S2a, Supporting
Information. The system allows long-term culture of HUVECs
under physiological flow conditions, inspection of the cells after
seeding and during their growth, and accurate control of the
flow rate and thus shear stress. This setup was used to run
the experiments for eight channels (i.e., four chips), simulta-
neously. A photographic representation of the setup can be seen
in Figure S2b, Supporting Information.
Based on in vivo measurements and fluid mechanical models,
vessels prone to atherosclerosis and dysfunction show decreased
shear stress (<4–5 dyne cm2).[43,44] Decreased shear stress can
disrupt vascular wall functions (e.g., reduction in endothelium
repair, decreased production of nitric oxide synthase [NOS],
Figure 2. Development of the En-on-a-chip. a) Schematic representation of the three-layered chip fabricated in this study and the dimensions of the chip
and channels. In this figure, a and b show the inlet and outlet of the upper channel and c and d show the inlet and outlet of the lower channel.
Photographic representation of the chip from b) top view, c) perspective view, and d) side view. e) Schematic representation of the chip after culturing
the cells on the membrane. f ) Confocal image showing the top view of the upper channel proves the full coverage of the membrane by HUVEC cells
(flow rate: 10 μLmin1, scale bar: 100 μm). Cells were stained for nucleus (blue), VE-cadherin (green), and F-actin (red).
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elevated production of reactive oxygen species [ROS], and higher
permeability of lipoproteins and leukocytes) and therefore results
in Dys-En and early-stage atherosclerosis.[44] In contrast, obstruc-
tive plaques in advanced atherosclerosis can significantly
increase shear stress.[45] In this study, we aimed to focus on
early-stage atherosclerosis. Therefore, we selected to use lower
shear stress (<4–5 dyne cm2). The optimized shear stress for
microfluidic cell culture not only should be in line with reported
in vivo conditions, but also should result in elongation of the cells
along the direction of the flow and support a healthy cell culture
without disruption of the cellular integrity. To find an optimized
shear stress, we performed the microfluidic cell culture using the
shear stress values of 0, 0.1, 1, 2, and 4 dyne cm2. Based on
Equation (1), the required flow rates for the shear stresses
of 0, 0.1, 1, 2, and 4 dyne cm2 were calculated to be 0, 1, 10,
20, and 40 μLmin1, respectively. As can be seen in Figure 3,
the low shear stress (0 and 0.1 dyne cm2) did not result in
the complete elongation of the cells along the direction of the
flow. In contrast, high shear stress (2 and 4 dyne cm2) disrupted
cellular connections and did not support healthy cell culture and
growth. Moderate shear stress (1 dyne cm2) showed elongation
of the cells and complete barrier integrity. Therefore, we selected
the shear stress of 1 dyne cm2 (flow rate of 10 μLmin1) as an
optimized condition for HUVEC culture and development of the
En-on-a-chip and Dys-En-on-a-chip in this study.
After culturing En-on-a-chip, tumor necrotic factor-α (TNF-α)
was used to induce Dys-En. TNF-α is a proinflammatory
cytokine, which is highly involved in the pathogenesis of
cardiovascular disorders.[46,47] TNF-α plasma levels in patients
suffering from cardiovascular disorders were reported to be
20 ngmL1.[48] In this study, media containing 20 ngmL1
of TNF-α was perfused through the developed En-on-a-chip,
and then three indicators of Dys-En, including the loss of vascu-
lar endothelial cadherin (VE-cadherin), formation of actin stress
fibers, and overexpression of VCAM-1 receptors, were investi-
gated by immunostaining and fluorescent microscopy (Figure 4).
VE-cadherin is a cellcell adhesion protein, which plays a key
role in endothelial barrier integrity and vascular permeability.[49]
The loss of VE-cadherin in endothelial cells results in endothelial
barrier disruption and thus enhanced permeability.[21,50] In this
study, the established En-on-a-chip showed the assembly of
VE-cadherin molecules at the cellular periphery, where they form
tight borders between endothelial cells. In contrast, Dys-En-on-a-
chip showed patchy expression of VE-cadherin and loss of VE-
cadherin connectivity at the cellular borders, which is an indica-
tor of intercellular gap formation and enhanced permeability
(Figure 4a). Furthermore, actin networks participate in endothe-
lial barrier integrity by binding to junctional proteins and stabi-
lizing them.[51] Therefore, healthy En shows the arrangement of
actin fibers at the cellular borders to establish endothelial junc-
tions. In contrast, Dys-En shows the formation of actin fibers in
central parts of the cells, known as actin stress fibers.[51] These
fibers cause transcellular tensions and cell contractions and
finally disrupt the barrier integrity.[51] In this study, the devel-
oped En-on-a-chip showed the arrangement of actin fibers at
the cellular periphery to form actin cortical rims. In contrast,
the developed Dys-En-on-a-chip could successfully show the for-
mation of actin stress fibers, which were prolonged in the central
domain of the endothelial cells (Figure 4b). Moreover, VCAM-1
immunostaining was performed to investigate the expression of
this molecule on the developed En-on-a-chip and Dys-En-on-a-
chip. VCAM-1 is an immunoglobulin-like adhesion molecule,
which is normally absent on healthy endothelial cells but rapidly
shows overexpression on inflamed and dysfunctional endothelial
cells.[23,52] The developed Dys-En-on-a-chip, in this study, suc-
cessfully showed a significant increase in VCAM-1 expression
compared with En-on-a-chip (Figure 4c). To quantify the fluores-
cent signals, imageJ software was used. The quantification of
VE-cadherin, F-actin, and VCAM-1 signals, respectively, showed
2.2-fold decrease, 1.9-fold increase, and 7.8-fold increase in Dys-
En-on-a-chip compared with En-on-a-chip. Therefore, the quan-
tification results confirmed the loss of VE-cadherin, formation of
Figure 3. Confocal images of En-on-a-chip under different shear conditions (i.e., 0, 0.1, 1, 2, and 4 dyne cm2). Cells were cultured under flow for 48 h and
then stained for VE-cadherin (green) and nucleus (blue) to visualize the orientation of the cells along the flow direction and endothelium integrity. Cells
cultured with the shear stress of 0 and 0.1 dyne cm2 did not show the complete elongation of the cells. Shear stress of 2 and 4 dyne cm2 resulted in
disrupted cellular connections and did not support healthy cell culture and growth. Some of the disrupted areas are marked by white arrowheads.
Moderate shear stress (1 dyne cm2) resulted in the elongation of the cells, while supporting the cellular integrity and being selected as the optimal
shear stress to culture HUVECs on chip in this study (scale bar: 50 μm).
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actin stress fibers, and overexpression of VCAM-1 in the devel-
oped Dys-En-on-a-chip in this study (Figure 4d–f ).
2.2. Permeability and Binding of VCAM-1-Targeted NPs Across
En-on-a-Chip and Dys-En-on-a-Chip
To gain understanding of which biophysicochemical properties
of NPs (i.e., size, charge, PDI, and targeting peptide density) have
the most influence on NP binding and translocation across the
Dys-En under biomimetic microfluidic conditions, VCAM-1-
targeted polystyrene NPs with different biophysicochemical
properties were synthesized. We selected polystyrene NPs as
model NPs for our experiments. These NPs are widely used
as model and reference NPs in vitro and in vivo due to their
low cytotoxicity, ease of synthesize, ease of size and surface
modification over a broad range, commercial availability, low
polydispersity, and high colloidal stability.[53–57] In this study,
amino-functionalized and rhodamine-labeled polystyrene NPs
with the size of 30, 60, 120, and 250 nm were abbreviated as
NP1, NP2, NP3, and NP4, respectively. The NPs were first
PEGylated using maleimide polyethylene glycol N-hydroxysucci-
nimidyl ester (Mal-PEG-NHS) and methoxy polyethylene
glycol N-hydroxysuccinimidyl ester (m-PEG-NHS) (Figure 5a).
Subsequently, the PEGylated NPs were conjugated with a
VCAM-1-targeting peptide (VHPKQHR-GGGC) (Figure 5b).
After NP preparation, they were characterized for their size, zeta
potential, PDI, and peptide density. Based on the dynamic light
scattering (DLS) technique, NP sizes for NP1, NP2, NP3, and
NP4 were, respectively, 49.3 1.1, 73.4 1.2, 122.9 2.5, and
281. 1 3.5 nm (Figure 6a). Furthermore, zeta potentials for
NP1, NP2, NP3, and NP4 were respectively 8.1 0.9,
7.5 0.4,8.3 0.8, and10.4 1.3mV (Figure 6b). In addi-
tion, this technique showed PDIs of 0.11 0.014, 0.02 0.015,
0.10 0.001, and 0.04 0.005 for NP1, NP2, NP3, and NP4,
respectively (Figure 6c). Based on UV spectroscopy, the number
of peptides per NP for NP1, NP2, NP3, and NP4 were, respec-
tively, 67.87 11.64, 437.84 30.72, 2996.51 150.89, and
75366.97 638.03. Therefore, peptide density per surface
unit of NPs can be calculated, which showed the density of
0.003 0.0006, 0.009 0.0006, 0.017 0.0009, and 0.078
Figure 4. Confocal images of a) VE-cadherin, b) F-actin, and c) VCAM-1 for En-on-a-chip and Dys-En-on-a-chip. To establish Dys-En, HUVECs were
cultured on the chip (10 μLmin1, 48 h) and then stimulated with TNF-α (20 ngmL1, 10 μLmin1, 12 h). The images are representative of three inde-
pendent experiments (scale bar: 50 μm). Quantification of d) VE-cadherin, e) F-actin, and f ) VCAM-1 signals confirmed the loss of VE-cadherin, formation
of actin stress fibers, and overexpression of VCAM-1, which are known as hallmarks of Dys-En. Data show mean SD (n¼ 5–7) and *** represents
statistically significant difference (p-value <0.001).
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0.003 nm2 for NP1, NP2, NP3, and NP4, respectively
(Figure 6d). After NP characterization, the permeability and
binding of the NPs across En-on-a-chip and Dys-En-on-a-chip
were studied (Figure 6e–h).
The permeability of NP1, NP2, NP3, and NP4 across En-on-a-
chip was 2.01 0.46%, 1.69 0.88%, 1.21 0.04%, and
0.21 0.10%, respectively. For Dys-En-on-a-chip, the permeabil-
ity of all NPs was higher than their permeability across En-on-a-
chip due to intercellular gaps, disrupted junctions, and compro-
mised integrity of Dys-En. The permeability of NP1, NP2, NP3,
and NP4 across Dys-En-on-a-chip was, respectively,
7.87 1.08%, 6.05 0.77%, 3.88 1.04%, and 0.51 0.10%
(Figure 6e). The binding of the NPs to En-on-a-chip and
Dys-En-on-a-chip was investigated by fluorescent microscopy.
The representative images can be seen in Figure 6f. To quantify
the results, mean fluorescent intensity (MFI) of rhodamine
(i.e., MFI of the NPs) and the exact number of nuclei (i.e., the
exact number of cells) were obtained and then MFI/cell was cal-
culated. The binding of NP1, NP2, NP3, and NP4 to En-on-a-
chip was, respectively, 2.5 0.41, 2.2 0.38, 1.6 0.27, and
1.8 0.9. However, their binding to Dys-En-on-a-chip was found
to be 20.02 0.8, 18.7 0.9, 8.3 0.6, and 11.7 1.2
(Figure 6g).
Consequently, based on the above-mentioned data: 1)
permeability across Dys-En was in the following order:
NP1>NP2>NP3>NP4. So, the smaller the NPs, the higher
their permeability. The larger NPs showed lower permeability,
even though they had higher peptide density. These results sug-
gest that size governs NP permeability regardless of peptide den-
sity. 2) NP binding to Dys-En was in the following order: NP1 and
NP2 (no significant difference) >NP4>NP3. So, the smaller
NPs showed the highest binding even though they had the lowest
peptide density. NP4, which had the highest peptide density
among all groups, was in the next place, followed by NP3.
Therefore, the results suggest that NP binding is first governed
by size and then peptide density. Finally, 3) in this study, no
trends were found between permeability and binding data with
PDI and zeta potential. The summary of the results can be seen
in Figure 6h, which shows the effect of the NP properties on their
permeability and binding across a Dys-En-on-a-chip.
Incorporating a porous membrane into a microfluidic device
has been previously used to study the permeability of fluorescent
tracers across endothelial layers.[58–61] Although the results of
these studies can be informative about the integrity and disrup-
tion of various endothelial layers, they cannot be used in the field
of nanomedicine to design optimal NPs to traverse these
Figure 5. Development of VCAM-1-targeting NPs in this study. a) PEGylation of the NPs using an amide bond coupling between NHS ester on the PEG
polymers and the amino functionality on the surface of the polystyrene NPs. b) The conjugation of the VCAM-1-targeting peptide to the surface of the NPs
based on maleimide-thiol reaction between the maleimide groups on the surface of the NPs and the SH group of the peptide.
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barriers. The reason is that the hydrodynamic diameter of these
tracers is much smaller than the diameter of typical NPs used in
nanomedicine. Only a few studies have been reported on the per-
meability of NPs across healthy and/or Dys-En under microflui-
dic flow. For instance, Wang et al. studied the permeability of two
types of NPs with different stiffnesses but similar sizes (70 nm)
across TNF-α-stimulated HUVECs.[62] The results showed simi-
lar permeability for these NPs, which indicates the dominant
effect of size on permeability. Also, Kim et al. studied the per-
meability of lipid NPs with a size of 70 nm across nonstimu-
lated and TNF-α-stimulated HUVECs.[9] The results showed a
significant increase in NP permeability across TNF-α-stimulated
cells compared with nonstimulated cells, which is in line with
our findings. However, none of these studies investigated the
effect of NP properties such as size and peptide density on their
permeability. In addition, Sasaki et al. developed a mathematical
model to investigate the relationship between the size of NPs and
their permeability across a microporousmembrane under micro-
fluidic flow.[63] Their model confirms the higher permeability of
smaller NPs, but the main limitation of their study is that the
membrane was without any cells. Therefore, the effect of
NPcell interactions on permeability was not considered.
Figure 6. Characterization and screening of the NPs across En-on-a-chip and Dys-En-on-a-chip in this study. Characterization of the NPs for their a) size,
b) zeta potential, c) PDI, and d) peptide density. e) Permeability of the NPs across En-on-a-chip and Dys-En-on-a-chip. f ) Representative images showing
the binding of the NPs to En-on-a-chip and Dys-En-on-a-chip. Red and blue colors show NPs and cell nuclei, respectively (scale bar: 20 μm).
g) Quantification of the binding results. h) Heat map summarizing the effect of NP properties on their permeability and binding across Dys-En-on-
a-chip. The results suggest that NP size is the most dominant factor, and smaller NPs show higher permeability and binding. In this figure, data show
mean SD of at least three independent experiments. *, **, and *** represent statistically significant differences with p-values of <0.05, <0.01, and
<0.001, respectively. ns represents nonsignificant differences.
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Various studies have demonstrated that models used to study
NP binding to cell adhesion molecules (CAMs) should reflect the
flow microenvironment and hemodynamics.[64–67] For instance,
Bhowmick et al. showed that flow and physiological adaption to
flow can control binding and endocytosis of NPs targeted to inter-
cellular adhesion molecule 1 (ICAM-1) in vitro and in vivo.[64] In
a similar study, Calderon et al. showed that ICAM-targeted NPs
tend to bind to capillary beds, where shear stress is minimal,
Figure 7. Restorative effect of Annexin A1 (20 μgmL1) on Dys-En. a) Schematic representation of Lucifer Yellow permeability across a membrane
(without any cells), En, Dys-En, and Annexin A1-treated Dys-En. b) Lucifer Yellow permeability results (5 μgmL1, 30min, 5 μl min1). Annexin A1 treat-
ment decreased Lucifer Yellow permeability, confirming the endothelial tightening. c) Immunostaining and confocal microscopy of VE-cadherin. White
frames show regions of interests (ROIs) enlarged in the second panel. d) Quantification of VE-cadherin signals by ImageJ. Annexin A1 treatment increased
the expression of this critical component of endothelial junctions. e) Real-time and f ) endpoint TEER measurements. Annexin A1 treatment increased the
TEER values, confirming its positive effect on endothelial integrity. In this figure, data show mean SD (n¼ 3–5). * and ** represent statistically signifi-
cant difference with p-value of <0.05 and <0.01, respectively.
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rather than binding to vascular areas subjected to
significant shear stress, where NPs need to overcome high hydro-
dynamic forces.[65] Furthermore, Han et al. investigated the
importance of flow on targeting of NPs to platelet endothelial cell
adhesion molecule 1 (PECAM-1). Their studies showed that
chronic and acute flow microenvironments can affect the NP tar-
geting mechanisms.[66,67] These studies emphasize the impor-
tance of flow microenvironment for binding of CAM-directed
NPs to endothelial cells. Moreover, the VCAM-1 binding to its
ligand has been reported to show catch-bond characteristics.[34,68]
The lifetime of a catch-bond initially increases by force because
the molecules deform and lock more tightly and then decreases
like in a normal bond.[69] Therefore, any mechanical force like
shear stress can affect VCAM-1 binding. Despite the important
role of shear in this field, only a few studies have used shear-gen-
erating systems when studying binding of CAM-targeted
NPs.[34,58,70–72] For instance, Kolhar et al. investigated the effect
of NP shape on ICAM-1 binding. They reported higher binding
of polystyrene nanorods compared with polystyrene nanospheres
with the same size and peptide density.[71] Muro et al. studied the
effect of dose and peptide density on binding of ICAM-1-targeted
NPs and reported the dose-dependent binding of NPs to TNF-α-
activated En.[72] Kusunose et al. synthesized a VCAM-1-targeting
liposome and studied the effect of peptide density on VCAM-1
binding. The results showed that the NP binding significantly
increases by increasing the peptide density.[34] Furthermore,
Campos et al. investigated the effect of NP shape on VCAM-1
binding under microfluidic flow. The results revealed that the
binding of rod-like NPs was significantly higher than the binding
of spherical NPs.[70] However, all studies were based on single-
sized NPs. To the best of our knowledge, the effect of NP size on
VCAM-1 binding under flow microenvironment has not been
reported.
2.3. Restorative Effect of Annexin A1 on Dys-En-on-a-Chip
To study the effect of Annexin A1 on Dys-En, we first measured
the translocation of Lucifer Yellow, as an endothelial permeabil-
ity marker, across the developed En-on-a-chip, Dys-En-on-a-chip,
and Annexin A1-treated Dys-En-on-a-chip (Figure 7a). Lucifer
Yellow is a hydrophilic and fluorescent tracer molecule, with
wide Stokes shift and distinct excitation/emission wavelength,
making it an ideal marker for robust permeability studies in cell
models.[73] The average intensity of the translocated Lucifer
Yellow across Dys-En-on-a-chip was 3.5-fold higher than
En-on-a-chip, which indicates the enhanced permeability and
compromised integrity of the developed Dys-En compared with
the healthy En. However, Annexin A1 treatment could signifi-
cantly lower the Lucifer Yellow translocation across the treated
Dys-En. The average intensity of translocated Lucifer Yellow
across Annexin A1-treated Dys-En-on-a-chip was 1.8-fold lower
than the nontreated Dys-En-on-a-chip, which confirmed the
endothelial tightening and the rescuing effect of Annexin A1
on permeability of Dys-En (Figure 7b).
Furthermore, immunostaining of VE-cadherin was performed
to investigate the distribution of this adherens junction compo-
nent for Dys-En-on-a-chip before and after Annexin A1 treatment
(Figure 7c–d). The results of confocal microscopy displayed a
patchy distribution of VE-cadherin and loss of cellcell connec-
tivity in nontreated Dys-En-on-a-chip. However, the treated
Dys-En-on-a-chip showed more distribution of VE-cadherin mol-
ecules at the cellular borders and higher connectivity of the junc-
tions (Figure 7c). The quantification of fluorescent signals by
ImageJ confirmed a 1.7-fold increase in VE-cadherin signals
in treated Dys-En-on-a-chip, compared with nontreated
Dys-En-on-a-chip (Figure 7d). Therefore, Annexin A1 treatment
of the developed Dys-En-on-a-chip could inhibit the loss of
VE-cadherin and/or enhance the expression of this critical com-
ponent of adherens junctions, further confirming the potential
use of Annexin A1 as a valuable drug candidate for CVDs.
In addition, we measured transendothelial electrical resistance
(TEER) for healthy En, Dys-En, and Annexin A1-treated Dys-En,
using an automated multiwell CellZscope device. TEER mea-
surement is a nondestructive and label-free method to study bar-
rier integrity. Intact and tightly connected endothelial cells are
resistant to the passage of electrical current but disrupted endo-
thelial layers allow the passage of the electrical current more
easily. Therefore, there is a direct relationship between the mea-
sured TEER and the integrity of the endothelial layer.[74]
Figure 7e shows the real-time TEER, and Figure 7f shows the
measured TEER at the end of the experiment (after 24 h), termed
“endpoint TEER.” As shown in these figures, Annexin A1
showed a positive effect on the integrity of endothelial layers.
The endpoint TEER for Dys-En was threefold less than healthy
En, which confirms the disrupted barrier integrity of the devel-
oped Dys-En model. However, Annexin A1 treatment could
increase the TEER values, and the endpoint TEER for treated
Dys-En was 1.5-fold higher than nontreated Dys-En, which indi-
cates the restorative effect of this protein on endothelial integrity.
3. Conclusion
In this study, a microchip consisting of two parallel channels
separated by a semipermeable membrane, which is a simple
but robust design for on-chip permeability studies, was utilized
to establish a Dys-En-on-a-chip model. The developed biomicro-
fluidic model not only can mimic the relevant pathological shear
stress but also showed loss of adherens junctions at cellular
borders, change of cytoskeleton organization to form actin stress
fibers, and upregulation of VCAM-1 on endothelial cells, which
are all indicators of a successful Dys-En biomimetic in vitro
model. The developed platform was used to screen several
VCAM-1-binding NPs with different properties. Based on the
NP translocation assessments and microscopy studies, smaller
NPs showed higher permeability and binding, and NP size dom-
inated the NP targeting to Dys-En. Moreover, the restorative
effect of Annexin A1 on Dys-En was investigated. Treatment
of Dys-En-on-a-chip with Annexin A1 resulted in restoration
of adherens junctions and enhancement of the barrier integrity,
which confirm the potential application for this drug to be used
clinically for the treatment of CVD such as atherosclerosis.
4. Experimental Section
Materials: SU-82 075 and PDMS (Sylgard 184) were purchased from
MicroChem (USA) and Dow Corning (USA), respectively. (3-aminopropyl)
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triethoxysilane (APTES), perfluorodecyltrichlorosilane (FDTS), phosphate
buffer saline (PBS), fetal bovine serum (FBS), penicillinstreptomycin,
fibronectin from human plasma, trypsin, ethylene diamine tetraacetic acid
(EDTA), Triton X-100, bovine serum albumin (BSA), dimethyl sulfoxide
(DMSO), cysteine, Lucifer Yellow, and ethanol were provided by Sigma-
Aldrich (Denmark). HUVECs (PCS-100-013), vascular cell basal medium
(PCS-100-030), and VE growth factor (VEGF) kit (PCS-100-041) were
obtained from American Type Cell Culture (ATCC, USA). Transwell inserts,
containing a PET porous membrane with the pore size of 1 μm, were pur-
chased from Corning (UK). TNF-α and recombinant human Annexin A1
were obtained from R and D systems (USA). Alexa fluor488 VE-cadherin
antibody was provided by Santa Cruz Biotechnology (USA). Alexa fluor647
Phalloidin, mouse monoclonal IgG1 anti-VCAM-1 antibody, and Alexa
fluor555-conjugated goat anti-mouse IgG1 antibody were obtained from
Invitrogen (Denmark). Polyether ether ketone (PEEK) tubing, Tygon tub-
ing, PEEK microtight adaptor, paraformaldehyde solution, and Hoechst
33342 were obtained from Thermo Fisher Scientific (Denmark).
Polystyrene NPs, which were functionalized by amine groups and labeled
by rhodamine B, were provided in four different sizes (i.e., 30, 60, 120, and
250 nm) byMicromod (Germany). VCAM-1-targeting peptide (VHPKQHR-
GGGC) was obtained from Mimotopes (UK). MAL-PEG-NHS (2 kDa) and
m-PEG-NHS (2 kDa) were obtained from Nanocs (USA).
Photolithography and Soft Lithography: Microfluidic channels were
designed using CleWin software (PhoeniX Technologies, USA) and then
patterned on a silicon wafer using SU-8 and standard photolithography
procedure (see Supporting Information and Figure S1). Subsequently,
silanization was performed to prevent the molds from sticking to
PDMS. For this purpose, the molds were silanized by FDTS using a molec-
ular vapor deposition (MVD) system (MVD 100, Applied Microstructures,
UK) for 60min. After mold fabrication and silanization, PDMS soft lithog-
raphy was performed.[75] Briefly, PDMS and its curing agent were mixed
(10:1 w/w ratio), degassed, poured over the mold, and baked at 80 C for
2 h. The cured PDMS slab was peeled from the mold and cut into
single devices (i.e., upper and lower layers of the chip). The access holes
to the channels were punched using a 1.25mm biopsy puncher on the
upper layer.
Bonding of PDMS Layers and Membrane: The upper layer was bonded
with a microporous PET membrane (Corning, 1 μm pore size, 1.6 106
pore cm2). For this purpose, the protocol developed by Aran et al.
was used.[76] Briefly, the membrane was activated in an oxygen plasma
chamber (600mTorr, 100W, Harrick Plasma, USA) for 1 min and then
immersed in 5% APTES solution at 80 C for 20min. Subsequently, the
PDMS upper layer was activated in an oxygen plasma chamber for
20 s, immediately brought into contact with the treated membrane, and
then heated at 80 C for 10min. Finally, the bonded laminate and the
PDMS lower layer were exposed to the oxygen plasma for 20 s and bonded
together considering the alignment of the channels. For accurate
alignment of the channels, a Dino-Lite microscope (AM7915MZTL,
Dino-Lite, UK) was used. Finally, the fabricated three-layered chip was
placed in an oven (60 C, overnight) to assure the complete bonding
of the layers.
Cell Line and Cell Maintenance: HUVECs were cultured in a vascular cell
basal medium, which was supplemented with VEGF kit, 10% FBS, and 1%
penicillinstreptomycin. The cells were cultured at 37 C in a humidified
incubator with 5% CO2. The media was changed every second day. The
cells were trypsinized after reaching 80% confluency, centrifuged at
100 g for 5 min, and resuspended in culture media at the required concen-
tration. For all experiments, the cells were used between passages 3 and 7.
Microfluidic Cell Culture Setup: The microfluidic cell culture setup used
in this study consisted of a microfluidic flow system, a microscope, a chip
holder, tubing, connectors, and reservoirs. The microfluidic flow system
consisted of a microfluidic pressure pump (MFCS-EX, with 8 channels,
Fluigent, Germany), a flow sensor (FRP8, Fluigent, Germany), caps for
pressurization of the media and collection reservoirs (Fluiwell-1C-
15mL, Fluigent, Germany), and a software to control and monitor the flow
rate (A-i-O software, Fluigent, Germany). The pressure pump was con-
nected to a local compressed air tap, which was equipped by a high-
precision regulator for adjusting the suitable inlet pressure to run the
pump (1300mBar). The light microscope and a flexible tabletop
microscope stand were purchased from Dino-Lite Inc. (AM7915MZTL
microscope, and RK-04 F stand, Dino-Lite, UK) to visualize the cells after
cell seeding and during culture. The chip holder with the total length,
width, and height of 15 10 2 cm was fabricated using polymethyl
methacrylate (PMMA) and a laser cutter machine (Epilog laser, USA).
The fabricated chip holder contained four separate holders with the dimen-
sions of 7.5 2.5 1 cm for four chips, which were bonded to microscopy
slides. The tubing connected to the flow sensor was PEEK tubing (with the
outer dimension of 0.75mm and the inner dimension of 125 μm). The
tubing connected to the chips was Tygon tubing (with the outer dimension
of 1.5 mm and the inner dimension of 0.5mm). These two tubes were
connected to each other using a PEEK microtight adaptor (for schematic
and photographic figures of the microfluidic setup, see Supporting
Information and Figure S2).
Development of En-on-a-Chip: First, all connectors, fittings, tubing, fil-
ters, reservoirs, and caps were sterilized by autoclaving. Then, they were
connected to the chips and the flow system inside a laminar flow hood
under sterilized conditions. To ensure the sterilization of the chips and
all components, the entire system was sterilized by perfusing 70% ethanol
for 30 min at the flow rate of 20 μLmin1. Subsequently, PBS was perfused
for 30min at the same flow rate. After preparation and sterilization of the
setup, it was placed in a cell-culture incubator (37 C, 5% CO2) for the rest
of the experiment duration. Then, 100 μgmL1 fibronectin solution was
perfused through the upper channels of the chips with the flow rate of
100 μLmin1 for 2 min, to coat the membranes. Then, the system was
statically incubated with the perfused fibronectin for 1 h. Following this,
HUVECs (1 107 cells mL1) were perfused through the upper channels
of the chips. The cell distribution was inspected using the microscope to
ensure complete and even seeding of the cells on the membrane. The cells
were incubated for 3 h under static condition to settle and adhere to the
membrane. Subsequently, the continuous flow of the culture media was
started at the flow rate of 10 μLmin1 (unless otherwise indicated). The
condition of the cells was regularly inspected using the microscope of the
system. After 48 h, the cells were found to reach confluency and establish a
healthy En-on-a-chip.
Development of Dys-En-on-a-Chip: HUVECs were grown to confluency as
mentioned earlier. Subsequently, TNF-α (20 ngmL1 in culture media)
was perfused through the upper channel for 12 h.
Shear Stress Calculation: To calculate shear stress from the flow data in











In this equation, τ and Q are shear stress and volumetric flow rate,
respectively. η is the viscosity of the fluid and assumed to be equal to
the viscosity of water at 37 C, which is 103 Pa.s. W is the width and
H is the height of the microchannel. f* (HW) is a correction factor, which
depends on the channel dimensions and the aspect ratio.[78] For the
designed microchannel in this study, the height-to-width ratio (HW) is
0.375. The calculated f* for the channel with this aspect ratio is reported
to be 0.7.[78]
Immunostaining and Quantification: For all steps of immunostaining
experiments, the reagent solutions were perfused through the upper chan-
nel at the flow rate of 100 μLmin1 for 2 min to deliver the reagents to the
cells. Then, the cells were incubated with the reagents under a stopped-
flow condition at room temperature. The solutions were introduced to the
cells in this order: PBS to rinse away the culture medium, 4% paraformal-
dehyde solution for 20 min to fix the cells, PBS to rinse, 0.1% Triton X-100
for 30min to permeabilize the cells, PBS to rinse, and 1% BSA solution for
1 h to block nonspecific bindings. Subsequently, cells were labeled with an
immunostaining antibody. For VE-cadherin staining, cells were incubated
with Alexa fluor488 VE-cadherin antibody (diluted 1:1000 in PBS) for
40min. In the case of F-actin staining, cells were incubated with Alexa
fluor647 Phalloidin (diluted 1:40 in PBS) for 1 h. For VCAM-1 staining, cells
were first incubated with mouse monoclonal IgG1 anti-VCAM-1 antibody
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(diluted 1:50 in PBS containing 1% BSA) for 1 h as the primary antibody.
Following that, cells were rinsed with PBS and incubated with Alexa
fluor555-conjugated goat antimouse IgG1 antibody (diluted 1:1000 in
PBS) for 1 h as the secondary antibody. For all experiments, nuclei staining
was performed using Hoechst (diluted 1:2000 in PBS) for 30 min. Finally,
confocal images were captured using a laser scanning confocal
microscope (LSM780, Zeiss, Germany).
To quantify the signals, three independent experiments were per-
formed, 5–7 images of each sample were obtained, and then all images
were quantified by imageJ software (ImageJ 1.47, USA). To quantify the
VE-cadherin signals in an image, the threshold value was selected by
the software and applied to the images. Then, the fluorescent intensity
above the threshold value was calculated by the software, normalized
to the number of nuclei in the image, and expressed as average VE-cad-
herin signal/cell. Using a single threshold value for all samples within an
experiment, the average VE-cadherin signal/cell was calculated for En-on-
a-chip and Dys-En-a-chip. Finally, data obtained from Dys-En-a-chip were
normalized to the data obtained from En-on-a-chip. To quantify F-actin
and VCAM-1 signals, a similar quantification method was performed.
Preparation of VCAM-1-Targeted Polystyrene NPs: For this purpose,
polystyrene NPs, which were functionalized by amine groups and labeled
by rhodamine B, were purchased from Micromod (Germany). NP solu-
tions were first washed twice in phosphate buffer (20 mM, pH 8). For this
purpose, NPs were centrifuged at 10 000 rpm, 4 C (30min for NP1, NP2,
and NP3, and 15min for NP4), using Amicon ultra-0.5 centrifugal filter
units (10 kDa cutoff, Millipore, UK) and then dissolved in 200 μL phos-
phate buffer. Then, NPs were PEGylated by a mixture of MAL-PEG-
NHS and m-PEG-NHS. In this study, we used MAL-PEG-NHS and m-
PEG-NHS with a molar ratio of 1:5 to avoid remaining of MAL groups
on the surface of the NPs, which can react with thiol groups on cells
and cell culture proteins. The PEG linkers were dissolved in DMSO
and then mixed with NP solutions at room temperature overnight. The
molar ratio of amine groups to PEG in these reactions was 1:3. Next,
the VCAM-1-targeting peptide was conjugated to the surface of the
NPs. For this purpose, the PEGylated NPs were washed twice in PBS buffer
containing 1mM EDTA and then reacted with an excess amount of the
peptide overnight at room temperature. Then, unreacted maleimide
groups were quenched using 20mM cysteine solution. Finally, the NPs
were washed twice in PBS using Amicon centrifugal filter units as
mentioned earlier.
Characterization of VCAM-1-Targeted Polystyrene NPs: Size, zeta poten-
tial, and PDI of the NPs were measured by DLS technique (DLS, Nano-ZS,
Malvern, UK). To quantify the peptide density on the surface of the NPs
(number of peptides per nm2 of NP surface or #peptide/nm
2), the UV
absorbance of the NPs was measured at 205 nm before and after peptide
coupling using a spectrophotometer (Nanodrop 2000, Thermo Fisher
Scientific, UK) and the difference of the absorbance (ΔA205) was obtained.
Moreover, the extinction coefficient (ε205) of the peptide at 205 nm was
calculated based on a model reported by Anthis et al.[79] and their online
computation program (available at: http://spin.niddk.nih.gov/clore).
Based on this model, the extinction coefficient of VHPKQHR-GGGC at
205 nm was 40 640 M1 cm1. Therefore, the concentration of the peptide
was calculated based on ε205 and ΔA205 results, using the BeerLambert
law. Finally, we calculated #peptide/nm
2 by knowing the concentration of
the peptide, NP size, and NP density (1.03 g cm3).
Permeability of VCAM-1-Targeted NPs across En-on-a-Chip and Dys-En-on-
a-Chip: NP solutions (100 μgmL1 in culture medium) were perfused
through the upper channel at the flow rate of 5 μLmin1. Moreover,
the culture medium without any NPs was perfused through the lower
channel at the flow rate of 1 μLmin1. After 6 h, the solution containing
translocated NPs was collected from the collection reservoir of the lower
channel. This solution was analyzed using a fluorescence plate reader
(Spark, Tecan Life Science, Switzerland) at the excitation/emission
wavelength of 552/580 nm to measure the fluorescent intensity of the
translocated NPs. Furthermore, standard curves were prepared to indicate
the relationship between the intensity and NP concentration. Based on the
intensity results and the standard curves, the concentration of the trans-
located NPs was calculated. Finally, the concentration of the translocated
NPs was divided by the initial concentration of the NPs to obtain percent
permeability.
Binding of VCAM-1-Targeted NPs to En-on-a-Chip and Dys-En-on-a-Chip:
For this purpose, the NP solution at the concentration of 100 μgmL1 was
perfused through the upper channel at the flow rate of 5 μLmin1 for 2 h.
Subsequently, the cells were washed extensively to remove any unbound
NP, fixed by 4% paraformaldehyde solution for 20min, stained for nucleus
by Hoechst (diluted 1:2000 in PBS) for 30 min, and then imaged using a
laser scanning confocal microscope (LSM780, Zeiss, Germany). Zen
Intellesis software (Zeiss, Germany) was used to quantify the images
and obtain the MFI of NPs and the exact number of cells for each image.
Then, MFI/cell was calculated.
Modulation of Dys-En-on-a-Chip by Annexin A1: First, Dys-En-on-a-chip
was developed as mentioned earlier. Then, 20 μgmL1 recombinant
human Annexin A1 was added to the TNF-α-containing medium and per-
fused through the upper channel at the flow rate of 10 μLmin1 for 12 h.
Lucifer Yellow Permeability Assay: Lucifer Yellow solution (5 μg mL1 in
culture medium) was perfused through the upper channel. The culture
medium without any fluorescent tracer was perfused through the lower
channel. The flow rate for both channels was set at 5 μLmin1. After
30min, the samples were collected from the collection reservoir of the
lower channel. The fluorescence intensity was measured using a fluores-
cence plate reader (Spark, Tecan Life Science, Switzerland) with excitation/
emission wavelength of 428/536 nm. For comparison, data were normal-
ized to the fluorescence intensity of the translocated Lucifer Yellow across
a bare membrane (a chip without any cells).
TEER Measurements: TEER was measured using CellZscope
(NanoAnalytics, Germany). First, cells were cultured on Transwell inserts,
containing a PET porous membrane with pore size of 1 μm. For this pur-
pose, the membranes were treated with 100 μgmL1 fibronectin for 1 h at
37 C. Then, HUVECs at the cell density of 0.2 106 cell/inserts were
seeded on the membranes and incubated for 24 h to form confluent endo-
thelial layers (En group). Then, the media in the inserts was exchanged
with the culture media containing 20 ngmL1 TNF-α, and the inserts were
incubated for 12 h (Dys-En group). Subsequently, 20 μgmL Annexin A1
was added to the inserts (Annexin A1 treated Dys-En group). Finally,
3–5 inserts of each group were placed inside the CellZscope device
and the TEER was measured every 30min, for the duration of 24 h.
The data obtained from the Dys-En group and Annexin A1-treated
Dys-En group were normalized to the data obtained from the En group.
Statistical Analysis: OriginPro 10 (OriginLab, USA) was used to perform
statistical analyses. All data were derived from at least three independent
experiments and reported as mean SD. The comparisons between
groups were made by two-sample t-test. The p-values of <0.05, <0.01,
and <0.001 were shown as *, **, and ***, respectively. The symbol
“ns” showed nonsignificant differences.
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